Hainsworth J D
Vanderbilt University, Nashville, TN.
Semin Oncol. 1992 Aug;19(4 Suppl 10):48-52.
The control of nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy has remained difficult, even with the use of combination antiemetic regimens containing metoclopramide. Although these patients receive a lower daily dose of cisplatin, the emetogenic potential remains high. In addition, many of the patients receiving multiple-day cisplatin regimens are young (eg, testicular cancer patients) and, therefore, have particular problems with the extrapyramidal side effects associated with metoclopramide. Studies show that ondansetron, used as a single antiemetic agent, is effective, safe, and well tolerated in the control of nausea and vomiting in patients receiving multiple-day cisplatin regimens.
即使使用包含甲氧氯普胺的联合止吐方案，接受多日顺铂化疗的患者的恶心和呕吐控制仍然困难。尽管这些患者每日接受的顺铂剂量较低，但其致吐潜力仍然很高。此外，许多接受多日顺铂方案的患者很年轻（例如睾丸癌患者），因此，他们在与甲氧氯普胺相关的锥体外系副作用方面存在特殊问题。研究表明，作为单一止吐药物使用的昂丹司琼，在控制接受多日顺铂方案患者的恶心和呕吐方面是有效、安全且耐受性良好的。
